Want to see AZTA full AI Analyst Report?
Top Page
Azenta
(NASDAQ:AZTA)
Select Model
Select Model
Rating:61Neutral
Price Target:
$42.00
▲(27.47% Upside)
Action:Reiterated
Date:10/07/26
AZTA scores as a moderate-risk, improving setup: strong technical uptrend and a solid balance sheet support the stock, while the earnings call showed better execution and raised outlook. The main constraints on the score are ongoing losses/negative margins, volatile free cash flow and margin pressures (including remediation costs), plus restructuring-related disruption risk and limited valuation support given negative earnings and no dividend yield.
Positive Factors
Recurring Revenue Base
A revenue base with more than half recurring can improve visibility and resilience across customer spending cycles. Growth in biorepositories and C&I also supports repeat consumables, service, and repository demand, strengthening customer relationships and providing a durable foundation for future execution.
Negative Factors
Persistent Losses and Margin Pressure
Sustained negative margins show that Azenta is not yet converting revenue into consistent profits, limiting internal capital generation and reducing the durability of its growth investments. Recent gross-margin deterioration adds evidence that operating costs, mix, and execution remain significant barriers to earnings improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring Revenue Base
A revenue base with more than half recurring can improve visibility and resilience across customer spending cycles. Growth in biorepositories and C&I also supports repeat consumables, service, and repository demand, strengthening customer relationships and providing a durable foundation for future execution.
Read all positive factors
Azenta Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down sales across regions to show where Azenta earns most of its revenue, revealing exposure to regional biotech demand, regulatory environments, and currency swings. Heavy concentration in a few markets raises risk, while diversified or expanding geography points to broader adoption of its sample-management, cold chain and genomics offerings.
Breaks down sales across regions to show where Azenta earns most of its revenue, revealing exposure to regional biotech demand, regulatory environments, and currency swings. Heavy concentration in a few markets raises risk, while diversified or expanding geography points to broader adoption of its sample-management, cold chain and genomics offerings.
Data provided by:
The Fly
The FlyAzenta (AZTA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.60B
Dividend Yield0.37%
Average Volume (3M)1.09M
Price to Earnings (P/E)―
Beta (1Y)1.11
Revenue Growth1.47%
EPS Growth-9.38%
CountryUS
Employees2,900
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-2.75
Shares Outstanding43,808,390
10 Day Avg. Volume867,214
30 Day Avg. Volume1,091,051
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)0.76
Price to Sales (P/S)2.21
P/FCF Ratio34.28
Enterprise Value/Market Cap0.55
Enterprise Value/Revenue1.44
Enterprise Value/Gross Profit3.26
Enterprise Value/Ebitda-9.12
Forecast
1Y Price Target
$35.00Price Target Upside6.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.52
Revenue Forecast (FY)$639.25M
Azenta Business Overview & Revenue Model
Company Description
Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other interna...
How the Company Makes Money
Azenta makes money by selling products and services that help customers store, track, process, and analyze biological samples and genetic data. A major revenue stream comes from sample management, which includes (1) the sale of automated storage s...
Azenta Earnings Call Summary
Earnings Call Date:Aug 04, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Nov 17, 2026
Earnings Call Sentiment Neutral
The call reflected a cautious but constructive tone: the company delivered a better-than-expected quarter with solid organic revenue growth (9%), sequential profitability improvement (adjusted EBITDA margin up ~610 bps sequentially) and progress on strategic initiatives (AI-enabled biorepository deployment, modular stores, UKBC integration, and B Medical divestiture). However, meaningful near-term headwinds remain — notably gross margin pressure (overall and in Sample Management Solutions), quality remediation costs ($5M–$6M expected), ongoing Sanger secular decline, negative quarterly free cash flow, and a difficult Q4 comp. Management emphasized disciplined execution and a measured outlook. Overall, positives around execution and a stronger outlook are balanced by persistent margin and demand uncertainties.Positive Updates
Revenue Beat and Organic Growth
Total revenue of $161.0M in Q3, up 12% reported and 9% organically, ahead of company expectations.
Negative Updates
Overall and SMS Gross Margin Pressure
Total gross margin was 46.2%, down 140 basis points year-over-year. Sample Management Solutions gross margin declined sharply, to 45.9% for the quarter, down ~750 basis points versus prior year, driven by automated stores, cryogenic systems, unfavorable fixed cost absorption and quality remediation.
Read all updates
Q3-2026 Updates
Positive
Negative
Revenue Beat and Organic Growth
Total revenue of $161.0M in Q3, up 12% reported and 9% organically, ahead of company expectations.
Read all positive updates
Company Guidance
Azenta updated its fiscal 2026 outlook, now expecting reported revenue of $613–$618 million and organic revenue roughly flat to up 1% year‑over‑year (improved from prior -2% to +1%); full‑year adjusted EBITDA is guided to $59–$62 million (Q4 adjusted EBITDA $20–$23 million) with Q4 organic revenue expected to decline low single digits versus a tough Q4 comp. Management expects full‑year free cash flow to improve ~10%–15% YoY, anticipates UK Biocentre will dilute margins by ~30 basis points, and reiterated remediation costs for automated stores of ~$5–$6 million for FY26 (about $1 million incurred in Q3). For context, Q3 revenue was $161 million (up 12% reported / 9% organic), Q3 adjusted EBITDA margin was ~11.4% (down 60 bps YoY, up 610 bps sequential), gross margin was 46.2% (down 140 bps), cash and equivalents were $529 million, and the company repurchased ~2.3 million shares for $50 million while completing the $63 million divestiture of B Medical Systems.Azenta Financial Statement Overview
Summary
Income Statement
42
Neutral
Balance Sheet
78
Positive
Cash Flow
51
Neutral
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 613.81M | 593.82M | 573.45M | 665.07M | 555.50M | 513.70M |
| Gross Profit | 270.37M | 270.28M | 254.62M | 233.26M | 230.62M | 214.51M |
| EBITDA | -96.60M | 54.07M | 71.62M | 55.15M | 48.35M | 9.94M |
| Net Income | -122.90M | -55.76M | -164.90M | -14.26M | -428.96M | 110.75M |
Balance Sheet | ||||||
| Total Assets | 1.88B | 2.06B | 2.10B | 2.89B | 3.72B | 1.82B |
| Cash, Cash Equivalents and Short-Term Investments | 325.80M | 340.92M | 462.09M | 1.02B | 1.57B | 227.51M |
| Total Debt | 53.97M | 111.17M | 70.68M | 60.44M | 49.23M | 94.77M |
| Total Liabilities | 366.08M | 330.70M | 331.07M | 351.22M | 352.74M | 494.18M |
| Stockholders Equity | 1.51B | 1.73B | 1.77B | 2.53B | 3.36B | 1.33B |
Cash Flow | ||||||
| Free Cash Flow | 9.88M | 38.32M | 12.35M | -33.60M | -543.48M | 97.05M |
| Operating Cash Flow | 37.98M | 72.18M | 49.74M | 5.83M | -466.05M | 149.86M |
| Investing Cash Flow | -72.43M | -90.46M | 224.74M | 431.38M | 1.47B | -146.35M |
| Financing Cash Flow | -51.16M | -9.59M | -659.21M | -840.46M | -62.76M | -25.91M |
Azenta Technical Analysis
Positive
32.95
Price Trends
34.47
Positive
30.43
Positive
28.34
Positive
Market Momentum
0.56
Positive
53.27
Neutral
57.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AZTA, the sentiment is Positive. The current price of 32.95 is below the 20-day moving average (MA) of 36.58, below the 50-day MA of 34.47, and above the 200-day MA of 28.34, indicating a neutral trend. The MACD of 0.56 indicates Positive momentum. The RSI at 53.27 is Neutral, neither overbought nor oversold. The STOCH value of 57.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AZTA.
Azenta Risk Analysis
Azenta disclosed 35 risk factors in its most recent earnings report. Azenta reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Azenta Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $54.18B | 59.91 | 3.79% | 2.00% | -2.56% | -40.38% | |
65 Neutral | $11.23B | 239.09 | 1.98% | ― | 16.49% | ― | |
64 Neutral | $11.69B | -20.61 | -10.34% | ― | -1.57% | -183.83% | |
61 Neutral | $1.60B | -13.27 | -7.56% | 0.37% | 1.47% | -9.38% | |
52 Neutral | $37.47M | -3.54 | -92.01% | ― | -1.06% | 82.17% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
AZTA
Azenta
36.50
4.62
14.49%
BDX
Becton Dickinson
198.91
55.51
38.71%
HBIO
Harvard Bioscience
8.23
4.21
104.73%
RGEN
Repligen
176.93
15.83
9.83%
AVTR
Avantor
17.29
2.18
14.43%
Azenta Corporate Events
Business Operations and Strategy
Azenta Restructures Multiomics Segment With Lab Closures
Negative
Oct 7, 2026
On October 5, 2026, Azenta’s board approved a restructuring plan for its Multiomics segment, aimed at consolidating its North American laboratory network and streamlining its organizational structure. The plan includes workforce reductions a...
Business Operations and StrategyExecutive/Board Changes
Azenta formalizes interim CEO pay and retention grants
Positive
Sep 17, 2026
On August 22, 2026, Azenta appointed Dr. Martin D. Madaus as interim president and chief executive officer and, on September 14, 2026, formalized his compensation with a $600,000 annual base salary, a performance recognition bonus equal to his bas...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Azenta Completes B Medical Divestiture With Loan Repayment
Positive
Sep 4, 2026
On September 4, 2026, Azenta announced that Thelema S.à r.l. had repaid in full, ahead of schedule, a $35 million secured vendor loan related to Azenta’s sale of B Medical Systems S.à r.l., which closed on July 1, 2026. The loan, e...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Azenta CEO Resigns as Interim Leader Reassures Outlook
Neutral
Aug 24, 2026
On August 22, 2026, Azenta announced that President and CEO John P. Marotta resigned from his executive roles and from the board, with the company stating his departure did not stem from any disagreement over operations or policies. The board simu...
Business Operations and StrategyM&A Transactions
Azenta Completes Strategic Divestiture to Streamline Portfolio
Positive
Jul 8, 2026
On July 1, 2026, Azenta Germany GmbH, a wholly owned subsidiary of Azenta, completed the sale of the entire share capital of B Medical Systems S.à r.l. to Thelema S.à r.l. for a fixed purchase price of $63 million. The deal, originally a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.